Selective Genomic Copy Number Imbalances and Probability of Recurrence in Early-Stage Breast Cancer

A number of studies of copy number imbalances (CNIs) in breast tumors support associations between individual CNIs and patient outcomes. However, no pattern or signature of CNIs has emerged for clinical use. We determined copy number (CN) gains and losses using high-density molecular inversion probe (MIP) arrays for 971 stage I/II breast tumors and applied a boosting strategy to fit hazards models for CN and recurrence, treating chromosomal segments in a dose-specific fashion (-1 [loss], 0 [no change] and +1 [gain]). The concordance index (C-Index) was used to compare prognostic accuracy between a training (n = 728) and test (n = 243) set and across models. Twelve novel prognostic CNIs were identified: losses at 1p12, 12q13.13, 13q12.3, 22q11, and Xp21, and gains at 2p11.1, 3q13.12, 10p11.21, 10q23.1, 11p15, 14q13.2-q13.3, and 17q21.33. In addition, seven CNIs previously implicated as prognostic markers were selected: losses at 8p22 and 16p11.2 and gains at 10p13, 11q13.5, 12p13, 20q13, and Xq28. For all breast cancers combined, the final full model including 19 CNIs, clinical covariates, and tumor marker-approximated subtypes (estrogen receptor [ER], progesterone receptor, ERBB2 amplification, and Ki67) significantly outperformed a model containing only clinical covariates and tumor subtypes (C-Index full model, train[test]  =  0.72[0.71] ± 0.02 vs. C-Index clinical + subtype model, train[test]  =  0.62[0.62] ± 0.02; p<10−6). In addition, the full model containing 19 CNIs significantly improved prognostication separately for ER–, HER2+, luminal B, and triple negative tumors over clinical variables alone. In summary, we show that a set of 19 CNIs discriminates risk of recurrence among early-stage breast tumors, independent of ER status. Further, our data suggest the presence of specific CNIs that promote and, in some cases, limit tumor spread.

[1]  Daniel Birnbaum,et al.  Gene expression profiling shows medullary breast cancer is a subgroup of basal breast cancers. , 2006, Cancer research.

[2]  R. Tibshirani,et al.  Repeated observation of breast tumor subtypes in independent gene expression data sets , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[3]  D. Madigan,et al.  Bayesian Model Averaging in Proportional Hazard Models: Assessing the Risk of a Stroke , 1997 .

[4]  M. Ringnér,et al.  High-resolution genomic and expression analyses of copy number alterations in HER2-amplified breast cancer , 2010, Breast Cancer Research.

[5]  Yudong D. He,et al.  Gene expression profiling predicts clinical outcome of breast cancer , 2002, Nature.

[6]  Y. Nakamura,et al.  Allelic losses of loci at 3p25.1, 8p22, 13q12, 17p13.3, and 22q13 correlate with postoperative recurrence in breast cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[7]  Harald Binder,et al.  Allowing for mandatory covariates in boosting estimation of sparse high-dimensional survival models , 2008, BMC Bioinformatics.

[8]  Robert Tibshirani,et al.  Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene‐expression subtypes of breast cancer , 2006, Genes, chromosomes & cancer.

[9]  James Ireland,et al.  Analysis of molecular inversion probe performance for allele copy number determination , 2007, Genome Biology.

[10]  Harald Binder,et al.  Boosting for high-dimensional time-to-event data with competing risks , 2009, Bioinform..

[11]  R. Gray.  Modeling Survival Data: Extending the Cox Model , 2002 .

[12]  Yusuke Nakamura,et al.  Association of allelic loss at 8p22 with poor prognosis among breast cancer cases treated with high-dose adjuvant chemotherapy. , 2002, Cancer letters.

[13]  S. Tavaré,et al.  High-resolution aCGH and expression profiling identifies a novel genomic subtype of ER negative breast cancer , 2007, Genome Biology.

[14]  Yusuke Nakamura,et al.  Allelic loss at the 8p22 region as a prognostic factor in large and estrogen receptor negative breast carcinomas , 2000, Cancer.

[15]  C. Sotiriou,et al.  Taking gene-expression profiling to the clinic: when will molecular signatures become relevant to patient care? , 2007, Nature Reviews Cancer.

[16]  A. Nobel,et al.  Supervised risk predictor of breast cancer based on intrinsic subtypes. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  E. S. Venkatraman,et al.  A faster circular binary segmentation algorithm for the analysis of array CGH data , 2007, Bioinform..

[18]  Wonshik Han,et al.  DNA copy number alterations and expression of relevant genes in triple‐negative breast cancer , 2008, Genes, chromosomes & cancer.

[19]  John M S Bartlett,et al.  Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  G. Hortobagyi,et al.  Ki‐67 immunostaining in node‐negative stage I/II breast carcinoma. Significant correlation with prognosis , 1991, Cancer.

[21]  D. Madigan,et al.  Correction to: ``Bayesian model averaging: a tutorial'' [Statist. Sci. 14 (1999), no. 4, 382--417; MR 2001a:62033] , 2000 .

[22]  Toshima Z. Parris,et al.  High-resolution genomic profiling to predict 10-year overall survival in node-negative breast cancer. , 2010, Cancer genetics and cytogenetics.

[23]  E. Milgrom,et al.  Ligand-controlled interaction of histone acetyltransferase binding to ORC-1 (HBO1) with the N-terminal transactivating domain of progesterone receptor induces steroid receptor coactivator 1-dependent coactivation of transcription. , 2006, Molecular endocrinology.

[24]  Ronald W. Davis,et al.  Multiplexed genotyping with sequence-tagged molecular inversion probes , 2003, Nature Biotechnology.

[25]  Thomas D. Wu,et al.  Genetic Alterations and Oncogenic Pathways Associated with Breast Cancer Subtypes , 2009, Molecular Cancer Research.

[26]  Christopher W. Wong,et al.  RCP is a human breast cancer-promoting gene with Ras-activating function. , 2009, The Journal of clinical investigation.

[27]  Adrian E. Raftery,et al.  Bayesian model averaging: a tutorial (with comments by M. Clyde, David Draper and E. I. George, and a rejoinder by the authors , 1999 .

[28]  Jude Kendall,et al.  Oncogenic cooperation and coamplification of developmental transcription factor genes in lung cancer , 2007, Proceedings of the National Academy of Sciences.

[29]  G. Mills,et al.  The RAB25 small GTPase determines aggressiveness of ovarian and breast cancers , 2004, Nature Medicine.

[30]  P. Nederlof,et al.  Array-CGH and breast cancer , 2006, Breast Cancer Research.

[31]  H. Dressman,et al.  Characterizing the developmental pathways TTF-1, NKX2–8, and PAX9 in lung cancer , 2009, Proceedings of the National Academy of Sciences.

[32]  Marcel J T Reinders,et al.  Imaging , Diagnosis , Prognosis Clinical Cancer Research Integration of DNA Copy Number Alterations and Prognostic Gene Expression Signatures in Breast Cancer Patients , 2010 .

[33]  G. Hortobagyi,et al.  Relationship between epidemiologic risk factors and breast cancer recurrence. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  P. Spellman,et al.  High quality copy number and genotype data from FFPE samples using Molecular Inversion Probe (MIP) microarrays , 2009, BMC Medical Genomics.

[35]  A. Vincent-Salomon,et al.  Identification of typical medullary breast carcinoma as a genomic sub-group of basal-like carcinomas, a heterogeneous new molecular entity , 2007, Breast Cancer Research.

[36]  D. Haber,et al.  Cancer: Drivers and passengers , 2007, Nature.

[37]  Ajay N. Jain,et al.  Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. , 2006, Cancer cell.

[38]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[39]  C. Perou,et al.  Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. , 2006, JAMA.

[40]  Tianji Chen,et al.  Dppa2 knockdown-induced differentiation and repressed proliferation of mouse embryonic stem cells. , 2010, Journal of biochemistry.

[41]  Christos Hatzis,et al.  Commercialized multigene predictors of clinical outcome for breast cancer. , 2008, The oncologist.

[42]  T. Lumley,et al.  Time‐Dependent ROC Curves for Censored Survival Data and a Diagnostic Marker , 2000, Biometrics.

[43]  J. Haerting,et al.  Gene-expression signatures in breast cancer. , 2003, The New England journal of medicine.

[44]  M. Wigler,et al.  Circular binary segmentation for the analysis of array-based DNA copy number data. , 2004, Biostatistics.

[45]  Y. Nakamura,et al.  Allelic losses as prognostic markers for breast cancers , 2001, International Journal of Clinical Oncology.

[46]  Daniel Birnbaum,et al.  Integrated profiling of basal and luminal breast cancers. , 2007, Cancer research.

[47]  Philippe Dessen,et al.  Molecular Characterization of Breast Cancer with High-Resolution Oligonucleotide Comparative Genomic Hybridization Array , 2009, Clinical Cancer Research.

[48]  Christian A. Rees,et al.  Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[49]  Jorma Isola,et al.  Patterns of chromosomal imbalances defines subgroups of breast cancer with distinct clinical features and prognosis. A study of 305 tumors by comparative genomic hybridization. , 2003, Cancer research.

[50]  Luke Hughes-Davies,et al.  Amplification of the BRCA2 Pathway Gene EMSY in Sporadic Breast Cancer Is Related to Negative Outcome , 2004, Clinical Cancer Research.